Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients
Status:
RECRUITING
Trial end date:
2028-11-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of chidamide combined with brentuximab vedotin regimen for CD30 positive PTCL patients who are unfit for chemotherapy.
Phase:
NA
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University